Stoke Therapeutics Inc. (STOK)
NASDAQ: STOK
· Real-Time Price · USD
22.95
0.10 (0.44%)
At close: Sep 25, 2025, 3:59 PM
22.94
-0.04%
After-hours: Sep 25, 2025, 05:11 PM EDT
0.44% (1D)
| Bid | 22.08 |
| Market Cap | 1.26B |
| Revenue (ttm) | 199.89M |
| Net Income (ttm) | 52.48M |
| EPS (ttm) | 0.87 |
| PE Ratio (ttm) | 26.38 |
| Forward PE | -8.02 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 24.39 |
| Volume | 1,142,388 |
| Avg. Volume (20D) | 1,017,365.5 |
| Open | 22.44 |
| Previous Close | 22.85 |
| Day's Range | 21.87 - 23.72 |
| 52-Week Range | 5.35 - 24.60 |
| Beta | 1.14 |
| Ex-Dividend Date | n/a |
About STOK
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol STOK
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for STOK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsStoke Therapeutics Inc. is scheduled to release its earnings on
Nov 4, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+24.98%
Stoke Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
2 months ago
+7.04%
Stoke Therapeutics shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced a price target of $30.
2 months ago · businesswire.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
